Category : Healthcare and Pharmaceuticals | Published at : November-2022 | Delivery Format : PDF | Status: Published | Pages : 250
The Global Chronic Obstructive Pulmonary Disease Treatment Market Size accounted for USD 16,784 Million in 2021 and is estimated to achieve a market size of USD 25,365 Million by 2030 growing at a CAGR of 4.9% from 2022 to 2030. The rise in the prevalence of chronic obstructive pulmonary disease (COPD) is predicted to drive the global chronic obstructive pulmonary disease (COPD) treatment market growth. Furthermore, continuous R&D and product lines for the diagnosis of chronic obstructive pulmonary disease are likely to fuel the worldwide chronic obstructive pulmonary disease treatment market value in the coming years.
Chronic Obstructive Pulmonary Disease Treatment Market Report Key Highlights
- Global chronic obstructive pulmonary disease treatment market revenue is estimated to expand by USD 25,365 million by 2030, with a 4.9% CAGR from 2022 to 2030.
- According to WHO, COPD is the third leading cause of death worldwide, accounting for 3.23 million deaths in 2019
- North America chronic obstructive pulmonary disease treatment market share accounted for over 41% of total market in 2021
- Asia-Pacific chronic obstructive pulmonary disease treatment market growth will observe highest CAGR from 2022 to 2030
- Among Distribution Channel, hospital pharmacies segment engaged more than 51.2% of the total market share
- Rapid technological developments in product innovation, drives the COPD treatment market size
Chronic Obstructive Pulmonary Disease (COPD) is a kind of chronic inflammatory respiratory problem that impairs circulation from the lungs. COPD symptoms include issues with breathing, mucous production, coughing, and wheezing.
Global Chronic Obstructive Pulmonary Disease Treatment Market Trends
Market Drivers
- Growth in the prevalence of COPD among people around the world
- Increasing rates of cigarette consumption among young individuals
- Rising public awareness concerning the usage of generic drugs
- Rapid technological developments in product innovation
Market Restraints
- Stringent government regulations
- High cost of COPD treatment
Market Opportunities
- Increased healthcare spending is giving amenities in developing countries.
- Increased investment in R&D by the government and major players
Chronic Obstructive Pulmonary Disease Treatment Market Report Coverage
| Market | Chronic Obstructive Pulmonary Disease Treatment Market |
| Chronic Obstructive Pulmonary Disease Treatment Market Size 2021 | USD 16,784 Million |
| Chronic Obstructive Pulmonary Disease Treatment Market Forecast 2030 | USD 25,365 Million |
| Chronic Obstructive Pulmonary Disease Treatment Market CAGR During 2022 - 2030 | 4.9% |
| Chronic Obstructive Pulmonary Disease Treatment Market Analysis Period | 2018 - 2030 |
| Chronic Obstructive Pulmonary Disease Treatment Market Base Year | 2021 |
| Chronic Obstructive Pulmonary Disease Treatment Market Forecast Data | 2022 - 2030 |
| Segments Covered | By Drug Class, By Distribution Channel, And By Geography |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled | Orion Corporation, Mylan N.V., AstraZeneca, Teva Pharmaceutical Industries Ltd., BoehringerIngelheim Pharmaceuticals, Inc., Novartis AG, GlaxoSmithKline plc, CHIESI Farmaceutici S.p.A., and Sunovion Pharmaceuticals, Inc. |
| Report Coverage |
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
The COPD treatment market value is driven by an increase in the numeral of COPD cases, an increase in FDA approval, and the continuous launch of a few products in the U.S. In addition, an increment in the geriatric populace and a rise in the use of pharmaceuticals in rising nations are alternate components adding to the development of the market. Nonetheless, the patent expiry of marked products and accessibility of conventional counterparts and elective treatment alternatives are foreseen to control the worldwide market.
High occurrence of COPD, promising medications in the pipeline, development of the pharmaceutical business in developing markets, for example, Asia Pacific, and launch of products, for example, inhalers are anticipated to increase the worldwide COPD treatment market growth from the year 2022 to 2030.
An increase in the commonness of COPD, high environmental contamination, increment in the geriatric populace, and development of the pharmaceutical business are foreseen to fuel the development of the chronic obstructive pulmonary disease (COPD) treatment market revenue in the Asia-Pacific. An article published in the International Journal of Pulmonary and Respiratory Sciences expressed that COPD is the third driving reason for death in India.
Chronic Obstructive Pulmonary Disease Treatment Market Segmentation
The worldwide chronic obstructive pulmonary disease treatment market segmentation is based on the drug class, distribution channel, and geography.
Chronic Obstructive Pulmonary Disease Treatment Market By Drug Class
- Bronchodilators
- Phosphodiesterase Type 4 Inhibitors
- Combination
- Corticosteroids
- Mucokinetics
- Others
According to a chronic obstructive pulmonary disease treatment industry analysis, the combination segment is expected to grow significantly in the market over the forecasting years. The combination segment has been segmented into long-acting beta-agonists & inhaled corticosteroids (LABA-ICS), triple therapy, long-acting muscarinic antagonist & inhaled corticosteroids (LAMA-ICS), and others. The bronchodilators segment has been bifurcated into short-acting beta agonist (SABA), long-acting beta-agonist (LABA), and long-acting muscarinic rival (LAMA). The combination segment is anticipated to represent the major share of the market by 2030 because of the increment in the number of doctors recommending combination treatment and the increase in the number of medications accessible for COPD treatment. The bronchodilators segment is foreseen to develop at a steady pace attributable to an increment in the appropriation of long-acting muscarinic rival (LAMA) drugs.
Chronic Obstructive Pulmonary Disease Treatment Market By Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
According to the chronic obstructive pulmonary disease treatment market forecast, the hospital pharmacies segment is predicted to grow at the fastest rate throughout the forecast period. This is due to an increase in the number of patients with chronic respiratory diseases as well as lifestyle disorders, as well as the heightened awareness of these illnesses. Furthermore, the availability of different diagnostic and treatment centers, increased purchasing power, as well as the availability of highly skilled healthcare professionals are driving growth in the segment.
Chronic Obstructive Pulmonary Disease Treatment Market Regional Outlook
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
The Middle East & Africa
- South Africa
- GCC Countries
- Rest of the Middle East & Africa (ME&A)
North America Holds The Major Share Of The Global Chronic Obstructive Pulmonary Disease Treatment Market
North America represented the biggest revenue share of the worldwide market in 2021. The presence of built-up pharmaceutical organizations, increment in the adoption of new drugs propelled in the market, and concentration on dispatch of new products through R&D are foreseen to drive the market in the area amid the estimated time frame.
The chronic obstructive pulmonary disease (COPD) treatment industry in Europe is driven by an increment in R&D spending and the introduction of new products. In November 2018, GlaxoSmithKline plc and Innoviva, Inc. got approval from the European Commission for extended use for once-daily TrelegyEllipta, the first single inhaler triple treatment demonstrated for COPD patients who were not enough treated with dual bronchodilation.
Chronic Obstructive Pulmonary Disease Treatment Market Players
Some of the top chronic obstructive pulmonary disease treatment market companies offered in the professional report include Orion Corporation, Mylan N.V., AstraZeneca, Teva Pharmaceutical Industries Ltd., BoehringerIngelheim Pharmaceuticals, Inc., Novartis AG, GlaxoSmithKline plc, CHIESI Farmaceutici S.p.A., and Sunovion Pharmaceuticals, Inc.
Frequently Asked Questions
The estimated value of global chronic obstructive pulmonary disease treatment market in 2021 was accounted to be USD 16,784 Million.
The projected CAGR chronic obstructive pulmonary disease treatment market during the analysis period of 2022 to 2030 is 4.9%.
The prominent players of the global chronic obstructive pulmonary disease treatment market are Orion Corporation, Mylan N.V., AstraZeneca, Teva Pharmaceutical Industries Ltd., BoehringerIngelheim Pharmaceuticals, Inc., Novartis AG, GlaxoSmithKline plc, CHIESI Farmaceutici S.p.A., and Sunovion Pharmaceuticals, Inc.
North America held the dominating chronic obstructive pulmonary disease treatment during the analysis period of 2022 to 2030.
Asia-Pacific region exhibited fastest growing CAGR for chronic obstructive pulmonary disease treatment during the analysis period of 2022 to 2030.
Growth in the prevalence of COPD and increasing rates of cigarette consumption among young individuals drives the growth of global chronic obstructive pulmonary disease treatment market.
Based on distribution channel, hospital pharmacies segment is expected to hold the maximum share of the chronic obstructive pulmonary disease treatment market.
